TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF? | Zendy

Ahmed ElGuindy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?

Author(s) -

Ahmed ElGuindy

Publication year - 2013

Publication title -

global cardiology science and practice

Language(s) - English

Resource type - Journals

ISSN - 2305-7823

DOI - 10.5339/gcsp.2013.42

Subject(s) - spironolactone , heart failure with preserved ejection fraction , medicine , heart failure , cardiology , aldosterone , clinical endpoint , ejection fraction , clinical trial

Heart failure with preserved ejection fraction (HFpEF) continues to be a challenging form of heart failure - one in which no therapy has yet been proven to improve outcome. Aldosterone antagonists have previously been shown to improve survival in a wide spectrum of patients with heart failure with reduced ejection fraction (HFrEF), and more recently, small trials suggested that they might have role in HFpEF patients. The effect of spironolactone on clinical outcomes in HFpEF was tested in the TOPCAT study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research